{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:08:32Z","timestamp":1790312912448,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03698-x","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T14:49:08Z","timestamp":1749221348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serum growth differentiation factor 15 associates with extra-glandular manifestations and disease activity of primary Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1038","volume":"15","author":[{"given":"Jinfang","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"9482","key":"3698_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox, R. I. Sjogren\u2019s syndrome. Lancet 366(9482), 321\u2013331. https:\/\/doi.org\/10.1016\/S0140-6736(05)66990-5 (2005).","journal-title":"Lancet"},{"key":"3698_CR2","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zeron","year":"2016","unstructured":"Brito-Zeron, P. et al. Sjogren syndrome. Nat Rev Dis Primers. 2, 16047. https:\/\/doi.org\/10.1038\/nrdp.2016.47 (2016).","journal-title":"Nat Rev Dis Primers."},{"issue":"7","key":"3698_CR3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00296-017-3715-4","volume":"37","author":"EJ Ter Borg","year":"2017","unstructured":"Ter Borg, E. J. & Kelder, J. C. Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjogren\u2019s syndrome\u202f: a long-term study of the antonius Nieuwegein sjogren (ANS) cohort. Rheumatol Int. 37(7), 1153\u20131158. https:\/\/doi.org\/10.1007\/s00296-017-3715-4 (2017).","journal-title":"Rheumatol Int."},{"issue":"2","key":"3698_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","volume":"53","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals, M. et al. Systemic involvement in primary Sjogren\u2019s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 53(2), 321\u2013331. https:\/\/doi.org\/10.1093\/rheumatology\/ket349 (2014).","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3698_CR5","doi-asserted-by":"publisher","first-page":"e000022","DOI":"10.1136\/rmdopen-2014-000022","volume":"1","author":"R Seror","year":"2015","unstructured":"Seror, R. et al. EULAR Sjogren\u2019s syndrome disease activity index (ESSDAI): a user guide. RMD Open 1(1), e000022. https:\/\/doi.org\/10.1136\/rmdopen-2014-000022 (2015).","journal-title":"RMD Open"},{"key":"3698_CR6","doi-asserted-by":"publisher","first-page":"109231","DOI":"10.1016\/j.intimp.2022.109231","volume":"112","author":"J Ji","year":"2022","unstructured":"Ji, J. et al. Hsa_circ_0008301 as a potential biomarker of disease activity for primary Sjogren\u2019s syndrome: Increased expression in peripheral blood of patients with primary Sjogren\u2019s syndrome. Int Immunopharmacol. 112, 109231. https:\/\/doi.org\/10.1016\/j.intimp.2022.109231 (2022).","journal-title":"Int Immunopharmacol."},{"issue":"2","key":"3698_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/03009742.2021.2001930","volume":"52","author":"X Yu","year":"2023","unstructured":"Yu, X. et al. Serum CCL28 as a biomarker for diagnosis and evaluation of Sjogren\u2019s syndrome. Scand J Rheumatol. 52(2), 200\u2013207. https:\/\/doi.org\/10.1080\/03009742.2021.2001930 (2023).","journal-title":"Scand J Rheumatol."},{"issue":"1","key":"3698_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13075-023-03229-x","volume":"26","author":"J Hong","year":"2024","unstructured":"Hong, J. et al. CXCL9 may serve as a potential biomarker for primary Sjogren\u2019s syndrome with extra-glandular manifestations. Arthritis Res Ther. 26(1), 26. https:\/\/doi.org\/10.1186\/s13075-023-03229-x (2024).","journal-title":"Arthritis Res Ther."},{"key":"3698_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813918","author":"A Caraba","year":"2023","unstructured":"Caraba, A., Iurciuc, S., Nicolin, M. & Iurciuc, M. Endothelial dysfunction in primary Sjogren\u2019s syndrome: Correlation with serum biomarkers of disease activity. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241813918 (2023).","journal-title":"Int J Mol Sci."},{"key":"3698_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112990","author":"K Johann","year":"2021","unstructured":"Johann, K., Kleinert, M. & Klaus, S. The role of GDF15 as a myomitokine. Cells https:\/\/doi.org\/10.3390\/cells10112990 (2021).","journal-title":"Cells"},{"issue":"1","key":"3698_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","volume":"63","author":"KC Wollert","year":"2017","unstructured":"Wollert, K. C., Kempf, T. & Wallentin, L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem. 63(1), 140\u2013151. https:\/\/doi.org\/10.1373\/clinchem.2016.255174 (2017).","journal-title":"Clin Chem."},{"key":"3698_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cytogfr.2021.11.002","volume":"64","author":"JA Siddiqui","year":"2022","unstructured":"Siddiqui, J. A. et al. Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia. Cytokine Growth Factor Rev. 64, 71\u201383. https:\/\/doi.org\/10.1016\/j.cytogfr.2021.11.002 (2022).","journal-title":"Cytokine Growth Factor Rev."},{"key":"3698_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000675","author":"A Amstad","year":"2020","unstructured":"Amstad, A. et al. Growth differentiation factor 15 is increased in stable MS. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000675 (2020).","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"7","key":"3698_CR14","doi-asserted-by":"publisher","first-page":"103058","DOI":"10.1016\/j.arcmed.2024.103058","volume":"55","author":"Q Wu","year":"2024","unstructured":"Wu, Q. et al. Activity prediction modeling based on a combination of growth differentiation factor 15 and serum biomarker levels in dermatomyositis and polymyositis. Arch Med Res. 55(7), 103058. https:\/\/doi.org\/10.1016\/j.arcmed.2024.103058 (2024).","journal-title":"Arch Med Res."},{"key":"3698_CR15","doi-asserted-by":"publisher","first-page":"926373","DOI":"10.3389\/fimmu.2022.926373","volume":"13","author":"WD Xu","year":"2022","unstructured":"Xu, W. D., Huang, Q., Yang, C., Li, R. & Huang, A. F. GDF-15: A potential biomarker and therapeutic target in systemic lupus erythematosus. Front Immunol. 13, 926373. https:\/\/doi.org\/10.3389\/fimmu.2022.926373 (2022).","journal-title":"Front Immunol."},{"key":"3698_CR16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2147\/JIR.S350281","volume":"15","author":"YW He","year":"2022","unstructured":"He, Y. W. & He, C. S. Association of growth and differentiation factor 15 in rheumatoid arthritis. J Inflamm Res. 15, 1173\u20131181. https:\/\/doi.org\/10.2147\/JIR.S350281 (2022).","journal-title":"J Inflamm Res."},{"issue":"2","key":"3698_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/1744666X.2022.2021879","volume":"18","author":"B De Paepe","year":"2022","unstructured":"De Paepe, B. Growth differentiation factor-15 as an emerging biomarker for identifying myositis. Expert Rev Clin Immunol. 18(2), 115\u2013123. https:\/\/doi.org\/10.1080\/1744666X.2022.2021879 (2022).","journal-title":"Expert Rev Clin Immunol."},{"key":"3698_CR18","doi-asserted-by":"publisher","first-page":"154966","DOI":"10.1016\/j.cyto.2019.154966","volume":"127","author":"B De Paepe","year":"2020","unstructured":"De Paepe, B., Verhamme, F. & De Bleecker, J. L. The myokine GDF-15 is a potential biomarker for myositis and associates with the protein aggregates of sporadic inclusion body myositis. Cytokine 127, 154966. https:\/\/doi.org\/10.1016\/j.cyto.2019.154966 (2020).","journal-title":"Cytokine"},{"key":"3698_CR19","doi-asserted-by":"publisher","first-page":"116475","DOI":"10.1016\/j.biopha.2024.116475","volume":"174","author":"BB Nyarady","year":"2024","unstructured":"Nyarady, B. B. et al. Growth and differentiation factor-15: A link between inflammaging and cardiovascular disease. Biomed Pharmacother. 174, 116475. https:\/\/doi.org\/10.1016\/j.biopha.2024.116475 (2024).","journal-title":"Biomed Pharmacother."},{"key":"3698_CR20","doi-asserted-by":"publisher","first-page":"1404047","DOI":"10.3389\/fendo.2024.1404047","volume":"15","author":"A Chiariello","year":"2024","unstructured":"Chiariello, A. et al. Different roles of circulating and intramuscular GDF15 as markers of skeletal muscle health. Front Endocrinol (Lausanne). 15, 1404047. https:\/\/doi.org\/10.3389\/fendo.2024.1404047 (2024).","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"3698_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/acr.21591","volume":"64","author":"SC Shiboski","year":"2012","unstructured":"Shiboski, S. C. et al. American College of Rheumatology classification criteria for Sjogren\u2019s syndrome: a data-driven, expert consensus approach in the Sjogren\u2019s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 64(4), 475\u2013487. https:\/\/doi.org\/10.1002\/acr.21591 (2012).","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"3698_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski, C. H. et al. 2016 American College of Rheumatology\/European league against rheumatism classification criteria for primary sjogren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 69(1), 35\u201345. https:\/\/doi.org\/10.1002\/art.39859 (2017).","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"3698_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/gerona\/gly153","volume":"74","author":"M Conte","year":"2019","unstructured":"Conte, M. et al. Human aging and longevity are characterized by high levels of mitokines. J Gerontol A Biol Sci Med Sci. 74(5), 600\u2013607. https:\/\/doi.org\/10.1093\/gerona\/gly153 (2019).","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"4","key":"3698_CR24","doi-asserted-by":"publisher","first-page":"L510","DOI":"10.1152\/ajplung.00062.2019","volume":"317","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. GDF15 is an epithelial-derived biomarker of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 317(4), L510\u2013L521. https:\/\/doi.org\/10.1152\/ajplung.00062.2019 (2019).","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"issue":"3","key":"3698_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11010-023-04743-x","volume":"479","author":"Y Wan","year":"2024","unstructured":"Wan, Y. & Fu, J. GDF15 as a key disease target and biomarker: Linking chronic lung diseases and ageing. Mol Cell Biochem. 479(3), 453\u2013466. https:\/\/doi.org\/10.1007\/s11010-023-04743-x (2024).","journal-title":"Mol Cell Biochem."},{"issue":"1","key":"3698_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12931-024-02824-z","volume":"25","author":"S Lu","year":"2024","unstructured":"Lu, S. et al. GDF15 ameliorates sepsis-induced lung injury via AMPK-mediated inhibition of glycolysis in alveolar macrophage. Respir Res. 25(1), 201. https:\/\/doi.org\/10.1186\/s12931-024-02824-z (2024).","journal-title":"Respir Res."},{"key":"3698_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acc.2023.02.003","volume":"114","author":"C Delrue","year":"2023","unstructured":"Delrue, C., Speeckaert, R., Delanghe, J. R. & Speeckaert, M. M. Growth differentiation factor 15 (GDF-15) in kidney diseases. Adv Clin Chem. 114, 1\u201346. https:\/\/doi.org\/10.1016\/bs.acc.2023.02.003 (2023).","journal-title":"Adv Clin Chem."},{"issue":"1","key":"3698_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. EULAR recommendations for the management of Sjogren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis. 79(1), 3\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216114 (2020).","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"3698_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri.2016.112","volume":"16","author":"W Chen","year":"2016","unstructured":"Chen, W. & Ten Dijke, P. Immunoregulation by members of the TGFbeta superfamily. Nat Rev Immunol. 16(12), 723\u2013740. https:\/\/doi.org\/10.1038\/nri.2016.112 (2016).","journal-title":"Nat Rev Immunol."},{"issue":"12","key":"3698_CR30","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1007\/s10067-023-06783-6","volume":"42","author":"J He","year":"2023","unstructured":"He, J. et al. Clinical significance of the expression levels of serum transforming growth factor-beta and CXC type chemokine ligand 13 in primary Sjogren\u2019s syndrome patients. Clin Rheumatol. 42(12), 3283\u20133288. https:\/\/doi.org\/10.1007\/s10067-023-06783-6 (2023).","journal-title":"Clin Rheumatol."},{"issue":"6","key":"3698_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.5114\/reum.2019.91276","volume":"57","author":"M Maslinska","year":"2019","unstructured":"Maslinska, M., Paradowska-Gorycka, A., Manczak, M., Kostyra-Grabczak, K. & Kwiatkowska, B. The level of TGF-beta in sera of patients with primary Sjogren\u2019s syndrome. Reumatologia 57(6), 309\u2013314. https:\/\/doi.org\/10.5114\/reum.2019.91276 (2019).","journal-title":"Reumatologia"},{"issue":"22","key":"3698_CR32","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1089\/scd.2017.0161","volume":"27","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. Effect of bone morphogenetic protein 6 on immunomodulatory functions of salivary gland-derived mesenchymal stem cells in sjogren\u2019s syndrome. Stem Cells Dev. 27(22), 1540\u20131548. https:\/\/doi.org\/10.1089\/scd.2017.0161 (2018).","journal-title":"Stem Cells Dev."},{"issue":"1","key":"3698_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10522-024-10164-0","volume":"26","author":"A Salminen","year":"2024","unstructured":"Salminen, A. GDF15\/MIC-1: A stress-induced immunosuppressive factor which promotes the aging process. Biogerontology 26(1), 19. https:\/\/doi.org\/10.1007\/s10522-024-10164-0 (2024).","journal-title":"Biogerontology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03698-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T14:49:08Z","timestamp":1749221348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03698-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3698"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03698-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of Xiangya Hospital, Central South University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"20007"}}